CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10146/51394
Title:
CYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.
Authors:
Tamer, L.; Ercan, B.; Ercan, S.; Ates, N.; Ates, C.; Ocal, K.; Dirlik, M.; Aydin, S.; Atik, U.
Abstract:
BACKGROUND: It has been reported that up to 80% of human cancers arise as a consequence of environmental exposure and host susceptibility factors. Environmental carcinogens are predominantly metabolized by the cytochrome P450 (CYP) superfamily of drug- or xenobiotic-metabolizing enzymes. Genetic variations in these enzymes affect individuals' susceptibility to carcinogens. AIM OF THE STUDY: The aim of this study was to evaluate the relationship between CYP2C19 polymorphism and susceptibility to these cancers by means of CYP2C19 genotyping among Turkish subjects. METHODS: DNAof subjects were isolated from leukocytes by high pure template preparation kit (Roche Diagnostics, GmbH, Mannheim, Germany) and genotypes were detected by LightCycler CYP2C19 Mutation Detection Kit by real-time PCR with LightCycler instrument (Roche Diagnostics, cat. no. 3113914). RESULTS: Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively). CONCLUSION: Although the frequency of CYP2C19*2 heterozygote genotype is high in our patients with gastric and colorectal carcinoma, there is no the relationship between CYP2C19 polymorphism and susceptibility to these cancer.
Citation:
J. Gastrointest. Cancer 2006, 37 (1):1-5.
Journal:
International journal of gastrointestinal cancer
Issue Date:
2006
URI:
http://hdl.handle.net/10146/51394
DOI:
10.1385/IJGC:37:1:1
PubMed ID:
17290075
Additional Links:
http://www.springerlink.com/content/n727j3212p412k30/
Type:
Article
Language:
en
Description:
Biomarkers of individual susceptibility: field studiesBiomarker: CYP2C19 polymorphismExposure/effect represented: environmental exposure to carcinogens / gastric and colorectal carcinoma riskStudy design: case-control studyAnalytical technique: CYP2C19 genotypes detected by Mutation Detection Kit using real-time PCRTissue/biological material/sample size: bloodImpact on outcome (including dose-response): Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively).
ISSN:
1537-3649
Appears in Collections:
Articles with annotation

Full metadata record

DC FieldValue Language
dc.contributor.authorTamer, L.-
dc.contributor.authorErcan, B.-
dc.contributor.authorErcan, S.-
dc.contributor.authorAtes, N.-
dc.contributor.authorAtes, C.-
dc.contributor.authorOcal, K.-
dc.contributor.authorDirlik, M.-
dc.contributor.authorAydin, S.-
dc.contributor.authorAtik, U.-
dc.date.accessioned2009-03-02T11:38:28Z-
dc.date.available2009-03-02T11:38:28Z-
dc.date.issued2006-
dc.identifier.citationJ. Gastrointest. Cancer 2006, 37 (1):1-5.en
dc.identifier.issn1537-3649-
dc.identifier.pmid17290075-
dc.identifier.doi10.1385/IJGC:37:1:1-
dc.identifier.urihttp://hdl.handle.net/10146/51394-
dc.descriptionBiomarkers of individual susceptibility: field studiesBiomarker: CYP2C19 polymorphismExposure/effect represented: environmental exposure to carcinogens / gastric and colorectal carcinoma riskStudy design: case-control studyAnalytical technique: CYP2C19 genotypes detected by Mutation Detection Kit using real-time PCRTissue/biological material/sample size: bloodImpact on outcome (including dose-response): Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively).en
dc.description.abstractBACKGROUND: It has been reported that up to 80% of human cancers arise as a consequence of environmental exposure and host susceptibility factors. Environmental carcinogens are predominantly metabolized by the cytochrome P450 (CYP) superfamily of drug- or xenobiotic-metabolizing enzymes. Genetic variations in these enzymes affect individuals' susceptibility to carcinogens. AIM OF THE STUDY: The aim of this study was to evaluate the relationship between CYP2C19 polymorphism and susceptibility to these cancers by means of CYP2C19 genotyping among Turkish subjects. METHODS: DNAof subjects were isolated from leukocytes by high pure template preparation kit (Roche Diagnostics, GmbH, Mannheim, Germany) and genotypes were detected by LightCycler CYP2C19 Mutation Detection Kit by real-time PCR with LightCycler instrument (Roche Diagnostics, cat. no. 3113914). RESULTS: Being male was associated with a 3.5-fold (OR: 4.27, CI: 2.27-8.05) and 4.27-fold (OR: 3.50, CI: 1.948-6.301) risk for colorectal and gastric carcinoma, respectively. The CYP2C19*3 heterozygote genotype was not found in either gastric or colorectal carcinoma patients. Although the frequency of CYP2C19*2 heterozygote genotype is high in patients with gastric and colorectal carcinoma, it is not significantly associated with cancer (OR: 1.79, CI: 0.829-3.865 and OR: 1.998, CI: 0.961-4.154, respectively). CONCLUSION: Although the frequency of CYP2C19*2 heterozygote genotype is high in our patients with gastric and colorectal carcinoma, there is no the relationship between CYP2C19 polymorphism and susceptibility to these cancer.en
dc.language.isoenen
dc.relation.urlhttp://www.springerlink.com/content/n727j3212p412k30/en
dc.subjectbiomarkers of individual susceptibility: field studiesen
dc.subjectblooden
dc.subjectGermanyen
dc.subjectmutationen
dc.subjectTurkeyen
dc.subjectfield studiesen
dc.subjectCYP2C19en
dc.subjectpolymorphismen
dc.subjectgastric and colorectal carcinomasen
dc.subject.meshAryl Hydrocarbon Hydroxylases-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshDNA, Neoplasm-
dc.subject.meshFemale-
dc.subject.meshGenetic Predisposition to Disease-
dc.subject.meshHeterozygote Detection-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMixed Function Oxygenases-
dc.subject.meshOdds Ratio-
dc.subject.meshPolymorphism, Genetic-
dc.subject.meshSex Characteristics-
dc.subject.meshStomach Neoplasms-
dc.subject.meshXenobiotics-
dc.titleCYP2C19 polymorphisms in patients with gastric and colorectal carcinoma.en
dc.typeArticleen
dc.identifier.journalInternational journal of gastrointestinal canceren

Related articles on PubMed

All Items in ECNIS-NIOM are protected by copyright, with all rights reserved, unless otherwise indicated.